Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?

Annals of Surgical Oncology

Volumn 21, Issue 5, 2014, Pages 1739-1748

  Heger, Ulrike ^a   Blank, Susanne ^a   Wiecha, Christiane ^a   Langer, Rupert ^b   Weichert, Wilko ^a   Lordick, Florian ^c   Bruckner, Thomas ^d   Dobritz, Martin ^e   Burian, Maria ^a   Springfeld, Christoph ^f   Grenacher, Lars ^a   Siewert, Jörg Rüdiger ^g   Büchler, Markus ^a   Ott, Katja ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADVANCED CANCER; ANASTOMOSIS LEAKAGE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DATA BASE; DISTANT METASTASIS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; FEMALE; HISTOPATHOLOGY; HUMAN; LOWER ESOPHAGUS SPHINCTER ADENOCARCINOMA; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE TREATMENT; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SIGNET RING CARCINOMA; STOMACH ADENOCARCINOMA; STOMACH CANCER; TREATMENT OUTCOME; TUMOR LOCALIZATION; TUMOR REGRESSION; WORLD HEALTH ORGANIZATION; ADENOCARCINOMA; CANCER GRADING; CARCINOMA, SIGNET RING CELL; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; ESOPHAGEAL NEOPLASMS; FOLLOW UP; LOWER ESOPHAGUS SPHINCTER; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDY; STOMACH NEOPLASMS; SURVIVAL RATE;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SIGNET RING CELL; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOGASTRIC JUNCTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84898901938     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3462-z     Document Type: Article

References (43)

1. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20.
2. Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715-21.
3. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28:5210-8.
4. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: An updated meta-analysis. Lancet Oncol. 2011;12:681-92.
5. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074-84.
6. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg. 1999;229:303-8. (Pubitemid 30191763)
7. Ott K, Fink U, Becker K, Stahl A, Dittler HJ, Busch R, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol. 2003;21:4604-10. (Pubitemid 46594034)
8. Becker K, Reim D, Novotny A, Zum Büschenfelde CM, Engel J, et al. Proposal for a multifactorial prognostic score that accurately classifies 3 groups of gastric carcinoma patients with different outcomes after neoadjuvant chemotherapy and surgery. Ann Surg. 2012;256:1002-7.
9. Blank S, Blaker H, Schaible A, Lordick F, Grenacher L, Buechler M, et al. Impact of pretherapeutic routine clinical staging for the individualization of treatment in gastric cancer patients. Langenbecks Arch Surg. 2012;397:45-55.
10. Ott K, Rachakonda PS, Panzram B, Keller G, Lordick F, Becker K, et al. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy. Ann Surg Oncol. 2011;18:2688-98.
11. Reim D, Gertler R, Novotny A, Becker K, zum Büschenfelde CM, Ebert M, et al. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer. Ann Surg Oncol. 2012;19:2108-18.
12. Wu H, Rusiecki JA, Zhu K, Potter J, Devesa SS. Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. Cancer Epidemiol Biomarkers Prev. 2009;18:1945-52.
13. Piessen G, Messager M, Leteurtre E, Jean-Pierre T, Mariette C. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg. 2009;250:878-87.
14. Li C, Kim S, Lai JF, Hyung WJ, Choi WH, Choi SH, et al. Advanced gastric carcinoma with signet ring cell histology. Oncology. 2007;72:64-8. (Pubitemid 350249131)
15. Messager M, Lefevre JH, Pichot-Delahaye V, Souadka A, Piessen G, Mariette C. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: A multicenter comparative study. Ann Surg. 2011;254:684-93; discussion 693.
16. Rougier P, Mahjoubi M, Lasser P, Ducreux M, Oliveira J, Ychou M, et al. Neoadjuvant chemotherapy in locally advanced gastric carcinoma - a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum. Eur J Cancer. 1994;30A:1269-75. (Pubitemid 24322060)
17. Takiuchi H, Hirata I, Kawabe S, Egashira Y, Katsu K. Immunohistochemical expression of vascular endothelial growth factor can predict response to 5-fluorouracil and cisplatin in patients with gastric adenocarcinoma. Oncol Rep. 2000;7:841-6.
18. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31-49.
19. Becker K, Langer R, Reim D, Novotny A, Meyer zum Buschenfelde C, Engel J, et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: A summary of 480 cases. Ann Surg. 2011;253:934-9.
20. Lorenzen S, Blank S, Lordick F, Siewert JR, Ott K. Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients. Ann Surg Oncol. 2012;19:2119-27.
21. Lorenzen S, Panzram B, Rosenberg R, Nekarda H, Becker K, Schenk U, et al. Prognostic significance of free peritoneal tumor cells in the peritoneal cavity before and after neoadjuvant chemotherapy in patients with gastric carcinoma undergoing potentially curative resection. Ann Surg Oncol. 2010;17:2733-9.
22. Ott K, Herrmann K, Schuster T, Langer R, Becker K, Wieder HA, et al. Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer. Ann Surg Oncol. 2011;18:3316-23.
23. Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K, et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res. 2008;14:2012-8. (Pubitemid 351551110)
24. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521-30. (Pubitemid 37151509)
25. Bader FG, Lordick F, Fink U, Becker K, Hofler H, Busch R, et al. Paclitaxel in the neoadjuvant treatment for adeno carcinoma of the distal esophagus (AEG I). A comparison of two phase II trials with long-term follow-up. Onkologie. 2008;31:366-72. (Pubitemid 351967573)
26. Fink U, Schuhmacher C, Stein HJ, Busch R, Feussner H, Dittler HJ, et al. Preoperative chemotherapy for stage III-IV gastric carcinoma: feasibility, response and outcome after complete resection. Br J Surg. 1995;82:1248-52.
27. Schuhmacher CP, Fink U, Becker K, Busch R, Dittler HJ, Mueller J, et al. Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up. Cancer. 2001;91:918-27.
28. Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg. 2001;234:360-7; discussion 368-9. (Pubitemid 32847073)
29. Wang SY, Yeh CN, Lee HL, Liu YY, Chao TC, Hwang TL, et al. Clinical impact of positive surgical margin status on gastric cancer patients undergoing gastrectomy. Ann Surg Oncol. 2009;16:2738-43.
30. Chan DS, Reid TD, Howell I, Lewis WG. Systematic review and meta-analysis of the influence of circumferential resection margin involvement on survival in patients with operable oesophageal cancer. Br J Surg. 2013;100:456-64.
31. Raziee HR, Cardoso R, Seevaratnam R, Mahar A, Helyer L, Law C, et al. Systematic review of the predictors of positive margins in gastric cancer surgery and the effect on survival. Gastric Cancer. 2012;15 Suppl 1:S116-24.
32. Chirieac LR, Swisher SG, Correa AM, Ajani JA, Komaki RR, Rashid A, et al. Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma. Clin Cancer Res. 2005;11:2229-36. (Pubitemid 40490181)
33. van Heijl M, van Lanschot JJ, Koppert LB, van Berge Henegouwen MI, Muller K, Steyerberg EW, et al. Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). BMC Surg. 2008;8:21.
34. Ott K, Blank S, Becker K, Langer R, Weichert W, Roth W, et al. Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10% residual tumor. Langenbecks Arch Surg. 2013;398:239-49.
35. Homann N, Pauligk C, Luley K, Werner Kraus T, Bruch HP, Atmaca A, et al. Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. Int J Cancer. 2012;130:1706-13.
36. Ajani JA, Correa AM, Walsh GL, Komaki R, Lee JH, Vaporciyan AA, et al. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer. 2010;116:1656-63.
37. Lordick F, Ott K, Weitz J, Jager D. The evolving role of catumaxomab in gastric cancer. Expert Opin Biol Ther. 2008;8:1407-15.
38. Sujendran V, Wheeler J, Baron R, Warren BF, Maynard N. Effect of neoadjuvant chemotherapy on circumferential margin positivity and its impact on prognosis in patients with resectable oesophageal cancer. Br J Surg. 2008;95:191-4.
39. Jass JR, Sobin LH, Watanabe H. The World Health Organization's histologic classification of gastrointestinal tumors. A commentary on the second edition. Cancer. 1990;66:2162-7.
40. Piessen G, Amielh D, Messager M, Vinatier E, Leteurtre E, Triboulet JP, et al. Is pretreatment endoscopic biopsy a good predictor of signet ring cell histology in gastric carcinoma? World J Surg. 2012;36:346-54.
41. Flucke U, Monig SP, Baldus SE, Zirbes TK, Bollschweiler E, Thiele J, et al. Differences between biopsy- or specimen-related Lauren and World Health Organization classification in gastric cancer. World J Surg. 2002;26:137-40. (Pubitemid 36920422)
42. Dikken JL, Coit DG, Klimstra DS, Rizk NP, van Grieken N, Ilson D, et al. Prospective impact of tumor grade assessment in biopsies on tumor stage and prognostic grouping in gastroesophageal adenocarcinoma: relevance of the seventh edition American Joint Committee on Cancer Staging Manual revision. Cancer. 2012;118:349-57.
43. Schneider PM, Metzger R, Schaefer H, Baumgarten F, Vallbohmer D, Brabender J, et al. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg. 2008;248:902-8.